semaglutide oral or injection Novo Nordisk launched an version of its GLP-1 injectable to US markets on Jan 5. Link in comments ACC 2025: Oral Semaglutide Reduces

Its ability to enhance glucose-dependent insulin secretion while suppressing glucagon release makes it particularly relevant in models of type 2 diabetes and insulin resistance

* Correspondence: Lorenzo Drago, [email protected] These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers

Semaglutide (Subcutaneous Route) Description and Brand Names - Mayo Clinic

Your PlexusDx provider can discuss whether dosing adjustments or alternative formulations (like lozenges or sprays) make sense for your situation

MS data confirmed correct molecular weight